x
Filter:
Filters applied
- JTO: Editors Choice
- Girard, NicolasRemove Girard, Nicolas filter
- Astaras, ChristoforosRemove Astaras, Christoforos filter
- August - November 2022Remove August - November 2022 filter
Author
- Aboubakar Nana, Frank1
- Addeo, Alfredo1
- Bar, Jair1
- Bettini, Adrienne1
- Calles, Antonio1
- Cuppens, Kristof1
- Decoster, Lynn1
- Derijcke, Sofie1
- Gantz-Sorotsky, Hadas1
- Hochmair, Maximilian1
- Häfliger, Simon1
- Kian, Waleed1
- Limon, Dror1
- Metro, Giulio1
- Moskovitz, Mor1
- Patel, Sandip1
- Peled, Nir1
- Reck, Martin1
- Rodriguez, Estelamari1
- Rotem, Ofer1
- Rottenberg, Yakir1
- Schokrpur, Shiruyeh1
- Wolner, Mirjana1
Editors Choice
1 Results
- Original Article Non-Small Cell Lung CancerOpen Access
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
Journal of Thoracic OncologyVol. 18Issue 2p169–180Published online: October 24, 2022- Jair Bar
- Nir Peled
- Shiruyeh Schokrpur
- Mirjana Wolner
- Ofer Rotem
- Nicolas Girard
- and others
Cited in Scopus: 3Approximately 10% of EGFR mutations (EGFRmuts) are uncommon (ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with ucEGFRmuts.